Physician profile

Lashea Young

Physician Assistant · Lillington, NC

NPI 1578029625

$1,332.84

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $238.84 2021-2022
Abbvie INC. $155.51 2021-2022
Organon LLC $155.20 2022
Astrazeneca Pharmaceuticals LP $104.66 2021-2022
Sanofi-Aventis U.S. LLC $94.00 2021-2022
Daiichi Sankyo INC. $67.63 2021-2022
Amarin Pharma, INC. $53.12 2021
Takeda Pharmaceuticals U.S.A., INC. $45.96 2021
Glaxosmithkline, LLC. $44.35 2021-2022
Amgen INC. $39.28 2021-2022
Biohaven Pharmaceuticals, INC. $33.89 2021
Currax Pharmaceuticals LLC $32.84 2021
Kowa Pharmaceuticals America, INC. $29.51 2021
Biohaven Pharmaceutical Holding Company LTD. $26.65 2022
Abbott Laboratories $22.86 2022
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $21.70 2022
Pfizer INC. $19.98 2021
Bausch Health US, LLC $19.41 2021
Ultragenyx Pharmaceutical INC. $19.09 2022
Irhythm Technologies, INC. $18.94 2022
Esperion Therapeutics, INC. $18.07 2021
Teva Pharmaceuticals USA, INC. $17.91 2022
Allergan, INC. $16.24 2021
Lilly USA, LLC $13.29 2021
Boehringer Ingelheim Pharmaceuticals, INC. $12.72 2021
Arbor Pharmaceuticals, INC. $11.19 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lashea Young

$1,332.84

in general payments reported 2019-2025

Years
2021-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/10604573/lashea-young

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.